CA3114325A1 - Ketamine composition for use in a method of treatment of depression by pulmonary administration - Google Patents
Ketamine composition for use in a method of treatment of depression by pulmonary administration Download PDFInfo
- Publication number
- CA3114325A1 CA3114325A1 CA3114325A CA3114325A CA3114325A1 CA 3114325 A1 CA3114325 A1 CA 3114325A1 CA 3114325 A CA3114325 A CA 3114325A CA 3114325 A CA3114325 A CA 3114325A CA 3114325 A1 CA3114325 A1 CA 3114325A1
- Authority
- CA
- Canada
- Prior art keywords
- composition
- ketamine
- administration
- dose
- esketamine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Otolaryngology (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18461615.9 | 2018-09-28 | ||
| EP18461615.9A EP3628313B1 (en) | 2018-09-28 | 2018-09-28 | Ketamine composition for use in a method of treatment of depression by pulmonary administration |
| PCT/EP2019/075735 WO2020064748A1 (en) | 2018-09-28 | 2019-09-24 | Ketamine composition for use in a method of treatment of depression by pulmonary administration |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3114325A1 true CA3114325A1 (en) | 2020-04-02 |
Family
ID=63713806
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3114325A Pending CA3114325A1 (en) | 2018-09-28 | 2019-09-24 | Ketamine composition for use in a method of treatment of depression by pulmonary administration |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US11925607B2 (https=) |
| EP (3) | EP3628313B1 (https=) |
| JP (1) | JP7444864B2 (https=) |
| KR (1) | KR102867739B1 (https=) |
| CN (1) | CN113038941A (https=) |
| AU (1) | AU2019349624B2 (https=) |
| BR (1) | BR112021005687A2 (https=) |
| CA (1) | CA3114325A1 (https=) |
| EA (1) | EA202190724A1 (https=) |
| ES (2) | ES3021221T3 (https=) |
| HU (2) | HUE071303T2 (https=) |
| MX (1) | MX2021003668A (https=) |
| PL (2) | PL3628313T3 (https=) |
| WO (1) | WO2020064748A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL3505157T3 (pl) | 2017-12-29 | 2022-04-11 | Celon Pharma S.A. | Kompozycja ketaminy w postaci suchego proszku do podawania dopłucnego w leczeniu depresji opornej na leczenie |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0009469D0 (en) * | 2000-04-17 | 2000-06-07 | Vectura Ltd | Improvements in or relating to formalities for use in inhaler devices |
| GB0523031D0 (en) * | 2005-11-11 | 2005-12-21 | Yaupon Therapeutics | Enhancement of morphine analgesia by s(-)-norketamine |
| WO2007111880A2 (en) | 2006-03-22 | 2007-10-04 | Mount Sinai School Of Medicine | Intranasal administration of ketamine to treat depression |
| DE102007009888A1 (de) | 2007-02-28 | 2008-09-04 | Hermann, Holger Lars, Dr. | Verwendung von S-(+)-Ketamin zur Behandlung von Depressionen |
| GB0908129D0 (en) * | 2009-05-12 | 2009-06-24 | Innovata Ltd | Composition |
| PE20141906A1 (es) | 2012-03-12 | 2014-12-05 | Janssen Pharmaceutica Nv | Esketamina para el tratamiento de la depresion refractaria al tratamiento o resistente al tratamiento |
| WO2014020155A1 (en) | 2012-08-02 | 2014-02-06 | Clinpharm Reform Gmbh | Oral transmucosal adminstration forms of s-ketamine |
| PE20200404A1 (es) | 2013-03-15 | 2020-02-26 | Janssen Pharmaceutica Nv | Composicion farmaceutica de clorhidrato de s-ketamina |
| CN116251084A (zh) | 2013-03-15 | 2023-06-13 | 詹森药业有限公司 | S-盐酸氯胺酮的药物组合物 |
| CN106714789A (zh) * | 2014-08-13 | 2017-05-24 | 詹森药业有限公司 | 用于治疗抑郁症的方法 |
| US20160338977A1 (en) * | 2015-05-20 | 2016-11-24 | Janssen Pharmaceutica Nv | Methods and kits for treating depression |
| CN106562952B (zh) * | 2015-10-09 | 2020-06-09 | 江阴安博生物医药有限公司 | 氯胺酮在治疗重性抑郁障碍中的应用 |
| PL3505157T3 (pl) * | 2017-12-29 | 2022-04-11 | Celon Pharma S.A. | Kompozycja ketaminy w postaci suchego proszku do podawania dopłucnego w leczeniu depresji opornej na leczenie |
-
2018
- 2018-09-28 EP EP18461615.9A patent/EP3628313B1/en active Active
- 2018-09-28 ES ES18461615T patent/ES3021221T3/es active Active
- 2018-09-28 PL PL18461615.9T patent/PL3628313T3/pl unknown
- 2018-09-28 HU HUE18461615A patent/HUE071303T2/hu unknown
-
2019
- 2019-09-24 EA EA202190724A patent/EA202190724A1/ru unknown
- 2019-09-24 PL PL19770131.1T patent/PL3856159T3/pl unknown
- 2019-09-24 US US17/281,136 patent/US11925607B2/en active Active
- 2019-09-24 BR BR112021005687-4A patent/BR112021005687A2/pt unknown
- 2019-09-24 EP EP19770131.1A patent/EP3856159B1/en active Active
- 2019-09-24 EP EP25162744.4A patent/EP4578505A3/en active Pending
- 2019-09-24 CA CA3114325A patent/CA3114325A1/en active Pending
- 2019-09-24 CN CN201980075601.XA patent/CN113038941A/zh active Pending
- 2019-09-24 ES ES19770131T patent/ES3028459T3/es active Active
- 2019-09-24 WO PCT/EP2019/075735 patent/WO2020064748A1/en not_active Ceased
- 2019-09-24 JP JP2021517252A patent/JP7444864B2/ja active Active
- 2019-09-24 MX MX2021003668A patent/MX2021003668A/es unknown
- 2019-09-24 KR KR1020217011554A patent/KR102867739B1/ko active Active
- 2019-09-24 HU HUE19770131A patent/HUE071649T2/hu unknown
- 2019-09-24 AU AU2019349624A patent/AU2019349624B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| PL3628313T3 (pl) | 2025-06-23 |
| JP2022502429A (ja) | 2022-01-11 |
| HUE071649T2 (hu) | 2025-09-28 |
| EP3628313A1 (en) | 2020-04-01 |
| EP3856159A1 (en) | 2021-08-04 |
| MX2021003668A (es) | 2021-08-19 |
| EP4578505A3 (en) | 2025-09-03 |
| US11925607B2 (en) | 2024-03-12 |
| EP3856159B1 (en) | 2025-03-12 |
| ES3021221T3 (en) | 2025-05-26 |
| EA202190724A1 (ru) | 2021-08-18 |
| KR20210068465A (ko) | 2021-06-09 |
| HUE071303T2 (hu) | 2025-08-28 |
| AU2019349624B2 (en) | 2025-08-28 |
| PL3856159T3 (pl) | 2025-06-16 |
| EP3856159C0 (en) | 2025-03-12 |
| US20210353560A1 (en) | 2021-11-18 |
| BR112021005687A2 (pt) | 2021-06-22 |
| ES3028459T3 (en) | 2025-06-19 |
| EP3628313B1 (en) | 2025-02-12 |
| EP4578505A2 (en) | 2025-07-02 |
| EP3628313C0 (en) | 2025-02-12 |
| JP7444864B2 (ja) | 2024-03-06 |
| KR102867739B1 (ko) | 2025-10-13 |
| WO2020064748A1 (en) | 2020-04-02 |
| AU2019349624A1 (en) | 2021-04-29 |
| CN113038941A (zh) | 2021-06-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12440440B2 (en) | Dry powder esketamine composition for use in the treatment of bipolar depression by pulmonary administration | |
| US20220230723A1 (en) | Electronically Supervised Administration of a Pharmaceutical Composition | |
| US20220226586A1 (en) | An Inhaler For Electronically Supervised Parenteral Administration of a Pharmaceutical Composition | |
| AU2019349624B2 (en) | Ketamine composition for use in a method of treatment of depression by pulmonary administration | |
| EA044969B1 (ru) | Композиция кетамина для применения в способе лечения депрессии путём ингаляционного введения | |
| EA046690B1 (ru) | Композиция кетамина в виде сухого порошка для применения при лечении депрессии ингаляционным путем | |
| AU2013100007A4 (en) | System for treating chronic obstructive pulmonary disease | |
| AU2013100008A4 (en) | Inhalable formulations of glycopyrronium bromide | |
| AU2013100009B4 (en) | Treatment of chronic obstructive pulmonary disease |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20220926 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD Year of fee payment: 5 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20240813 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20240813 Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20240813 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20241007 |
|
| D00 | Search and/or examination requested or commenced |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D00-D120 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: VOLUNTARY SUBMISSION OF PRIOR ART RECEIVED Effective date: 20241108 |
|
| D00 | Search and/or examination requested or commenced |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D00-D123 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: PRIOR ART DISCLOSURE DETERMINED COMPLIANT Effective date: 20241230 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20241230 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20241230 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20241230 Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20241230 |
|
| R11 | Change to the name of applicant or owner or transfer of ownership requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-R10-R11-R127 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: TRANSFER RECORDAL REQUEST OR RESPONSE Effective date: 20250110 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250110 |
|
| R14 | Transfer of ownership recorded |
Free format text: ST27 STATUS EVENT CODE: A-2-2-R10-R14-R129 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: TRANSFER REQUIREMENTS DETERMINED COMPLIANT Effective date: 20250505 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 6TH ANNIV.) - STANDARD Year of fee payment: 6 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250704 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250704 |
|
| D22 | Grant of ip right intended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D22-D128 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALLOWANCE REQUIREMENTS DETERMINED COMPLIANT Effective date: 20250828 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20250828 |